The partnership aims to further the AI-driven discovery of novel spatial biomarkers – indicators of recurrence, response to treatment or prognosis in solid tumors.
Nucleai is developing an artificial intelligence-based precision oncology platform for research and treatment decisions.
In March the company announced $33 million in a Series B funding round to further expand its spatial biology platform, bringing its total funding to nearly $50 million.
The newly-announced collaboration combines Nucleai’s powerful AI spatial analytics platform with Sirona Dx’s expertise to uncover novel spatial signatures that infer therapy response to therapy and direct treatment decisions. Sirona Dx will serve as a contract research partner to Nucleai and its consumers to further the use of AI-based diagnostics to support biopharma clinical trials.
“Multiplex imaging technologies have improved rapidly over the years; however, identifying actionable insights from all the data collected remains immensely challenging,” says Avi Veidman, Co-Founder and Chief Executive Officer of Nucleai. “This powerful synergy between Sirona Dx and Nucleai is very exciting as it will allow us to identify actionable spatial signatures that can predict response to immunotherapy.”
Nucleai, founded in 2017, developed a platform for pharmaceutical companies, organizations, and laboratories that leverages tissue datasets to produce insights into cancer biology, increase clinical trial efficacy, and improve patient care. The company aims to unlock the power of pathology data, thus transforming drug development and clinical treatment. Nucleai’s AI-powered spatial biology algorithm supports a variety of image modalities and cancer indications, allowing for a customizable and deployable solution in drug development.
Sirona Dx is recognized as a leading provider of multiomic single-cell analytic services and a pioneer of spatial biology technology in 2018. The company’s technology-agnostic spatial biology suite includes multiplexed imaging platforms to develop high-performance assays.
“We are delighted to announce a partnership with Nucleai,” said Andrew Brown, Ph.D. Chief Commercial Officer at Sirona Dx. “Nucleai’s AI-driven analytical capabilities are exceptional. Our combined expertise in multiplexed tissue assay development, data generation, and state-of-the-art analysis will unlock new spatial insights and accelerate the spatial biology revolution in precision medicine.”